Pathogenesis of human immunodeficiency virus-induced neurological disease

Journal of NeuroVirology

Volumn 9, Issue 2, 2003, Pages 222-227

  Albright, Andrew V ^a   Soldan, Samantha S ^a   González Scarano, Francisco ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Entry; HIV; Neuropathogenesis

Indexed keywords

ABACAVIR; ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

APOPTOSIS; BLOOD BRAIN BARRIER; CENTRAL NERVOUS SYSTEM INFECTION; CEREBROSPINAL FLUID; CHOROID PLEXUS; DISEASE SEVERITY; DRUG BRAIN LEVEL; DRUG PENETRATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS ENCEPHALITIS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; NERVE CELL LESION; NEUROBIOLOGY; NEUROLOGIC DISEASE; PRIORITY JOURNAL; REVIEW; VIRUS ENCEPHALITIS; VIRUS PATHOGENESIS; VIRUS REPLICATION;

HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 0038136866     PISSN: 13550284     EISSN: None     Source Type: Journal    
DOI: 10.1080/13550280390194073     Document Type: Review

References (50)

1. Adamson DC, Kopnisky KL, Dawson TM, Dawson VL (1999). Mechanisms and structural determinants of HIV-1 coat protein. Gp41 induced neurotoxicity. J Neurosci 19: 64-71.
2. Ahlquist P (2002). RNA-dependent RNA polymerases, viruses and RNA silencing. Science 296: 1270-1273.
3. Bagasra O, Lavi E, Bobroski L, Khalili K, Pestaner JP, Tawadros R, Pomerantz RJ (1996). Cellular reservoirs of HIV-1 in the central nervous system of infected individuals: identification by the combination of in situ polymerase chain reaction and immunohistochemistry. AIDS 10: 573-585.
4. Bezzi P, Domercq M, Brambilla L, Galli R, Schols D, De Clercq E, Vescovi A, Bagetta G, Kollias G, Meldolesi J, Volterra A (2001). CXCR4-activated astrocyte glutamate release via TNF alpha: amplification by microglia triggers neurotoxicity. Nat Neurosci 4: 676-678.
5. Bragg DC, Childers TA, Tompkins MB, Tompkins W, Meeker RB (2002). Infection of the choroids plexus by feline immunodeficiency virus. J Neuro Virol 8: 211-224.
6. Chen W, Sulcove J, Frank I, Jaffer S, Ozdener H, Kolson DL (2002). Development of a human neuronal cell model for human immunodeficiency virus (HIV)-infected macrophage-induced neurotoxicity: apoptosis induced by HIV type 1 primary isolates and evidence for involvement of the Bcl-2/Bcl-xL-sensitive intrinsic apoptosis pathway. J Virol 76: 9407-9419.
7. Edinger AL, Blanpain C, Kunstman KJ, Wolinsky SM, Parmentier M, Doms RW (1999). Functional dissection of CCR5 coreceptor function through the use of CD4-independent simian immunodeficiency virus strains. J Virol 73: 62-73.
8. Gendelman HE, Lipton SA, Tardiru M, Bukrinsky MI, Nottet HSLM (1994). The neuropathogenesis of HIV-1 infection. J Leukoc Biol 56: 389-398.
9. Georgsson G (1994). Neuropathologic aspects of lentiviral infections. Ann N Y Acad Sci 724: 50-67.
10. Gorry PR, Taylor J, Holm GH, Mehle A, Morgan T, Cayabyab M, Farzan M, Wang H, Bell JE, Kunstmann K, Moore JP, Wolinsky SM, Gabuzda D (2002). Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol 76: 6277-6292.
11. Gray F, Lescs M, Keihane C, Paraire F, Marc B, Durigon M, Gherardi R (1992). Early brain changes in HIV infecton: neuropathological study of 11 HIV seropositive non-AIDS cases. J Neuropathol Exp Neurol 51: 177-185.
12. Harouse JM, Wroblewska Z, Laughlin MA, Hickey WF, Schonwetter BS, González-Scarano F (1989). Human choroid plexus cells can be latently infected with human immunodeficiency virus. Ann Neurol 25: 406-411.
13. Johnston JB, Zhang K, Silva C, Shalinsky DR, Conant K, Ni W, Corbett D, Young VW, Power C (2001). HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Ann Neurol 49: 230-241.
14. Kanmogne GD, Kennedy RC, Gramas P (2002). HIV-1 gp120 proteins and gp160 peptides are toxic to brain endothelial cells and neurons: possible pathway for HIV entry into the brain and HIV-associated dementia. J Neuropathol Exp Neurol 61: 992-1000.
15. Kaul M, Lipton SA (1999). Chemokines and activated macrophages in HIV gp120-induced neuronal apoptosis. Proc Natl Acad Sci U S A 96: 8212-8216.
16. Kelder W, McArthur JC, Nance-Sproson T, McClernon D, Griffin DE (1998). β-Chemokines MCP-1 and RANTES are selectively increased in cerebrospinal fluid of patients with human immunodeficiency virus-associated dementia. Ann Neurol 44: 831-835.
17. Kennedy DW, Abkowitz JL (1997). Kinetics of central nervous system microglial and macrophage engraftment: analysis using a transgenic bone marrow transplantation model. Blood 90: 986-993.
18. Koenig S, Gendelman HE, Orenstein JM, Dal Canto MC, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS (1986). Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 233: 1089-1093.
19. Kolchinsky P, Kiprilov E, Bartley P, Rubinstein R, Sodroski J (2001). Loss of a single N-linked glycan allows CD4-independent human immunodeficiency virus type 1 infection by altering the position of the gp120 V1/V2 variable loops. J Virol 75: 3435-3443.
20. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PWIH, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J (2002). HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
21. Liu NQ, Lossinsky AS, Popik W, Li X, Gujuluva C, Kriederman B, Roberts J, Pushkarsky T, Bukrinsky M, Witte M, Weinand M, Fiala M (2002). Human immunodeficiency virus type 1 enters brain microvascular endothelia by macropinocytosis dependent on lipid rafts and the mitogen-activated protein kinase signaling pathway. J Virol 76: 6689-6700.
22. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S (2000). Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neuro Virol 6: S70-S81.
23. Martín J, LaBranche CC, González-Scarano F (2001). Differential CD4/CCR5 utilization, gp120 conformation and neutralization sensitivity between envelopes from a microglia-adapted human immunodeficiency virus type 1 and its parental isolate. J Virol 75: 3568-3580.
24. Maschke M, Kastrup O, Esser S, Ross B, Hengge U, Hufnagel A (2000). Incidence and prevalence of neurological disorders associated with HIV since the introduction of highly active anti-retroviral therapy (HAART). J Neurol Neurosurg Psychiatry 69: 257-260.
25. Masliah E, DeTeresa RM, Mallory ME, Hansen LA (2000). Changes in pathological findings at autopsy in AIDS cases for the last 5 years. AIDS 14: 69-74.
26. Massari FE, Poli G, Schnitman SM, Psallidopoulous MC, Darvey V, Fauci AS (1990). In vivo T lymphocyte origin of macrophage-tropic strains of HIV. Role of monocytes during in vitro isolation and in vivo infection. J Immunol 144: 4628-4632.
27. Mayhan WG (2002). Cellular mechanisms by which tumor necrosis factor-alpha produces disruption of the blood-brain barrier. Brain Res 927: 144-152.
28. Mayne M, Holden CP, Nath A, Geiger JD (2000). Release of calcium from inositol 1,4,5-triphosphate receptor-regulated stores by HIV-1 Tat regulates TNF-alpha production in human macrophages. J Immunol 164: 6538-6542.
29. McArthur JC, Hoover DR, Bacellar H, et al (1993). Dementia in AIDS patients: incidence and risk factors. Neurology 43: 2245-2251.
30. McManus CM, Weidenheim K, Woodman SE, Nunez J, Hesselgesser J, Nath A, Berman JW (2000). Chemokine and chemokine-receptor expression in human glial elements: induction by the HIV protein Tat, and chemokine autoregulation. Am J Pathol 156: 1441-1453.
31. Miller G (2002). Breaking down barriers. Science 297: 1116-1118.
32. Mukhtar M, Harley S, Chen P, BouHamdan M, Patel C, Acheampong E, Pomerantz R (2002). Primary isolated human brain microvascular endothelial cells express diverse HIV/SIV-associated chemokine coreceptors and DC-SIGN and L-SIGN. Virology 297: 78-88.
33. Nath A (1999). Pathobiology of human immunodeficiency virus dementia. Semin Neurol 19: 113-127.
34. Patel CA, Mukhtar M, Harley S, Kulkosky J, Pomerantz RJ (2002). Lentiviral expression of HIV-1 V pr induces apoptosis in human neurons. J Neuro Virol 8: 86-99.
35. Petito CK, Chen H, Mastri AR, Torres-Munoz J, Roberts B, Wood C (1999). HIV infection of choroid plexus in AIDS and asymptomatic HIV-infected patients suggests that the choroid plexus may be a reservoir of productive infection. J Neuro Virol 5: 670-677.
36. Powderly WG (2000). Current approaches to treatment for HIV-1 infection. J Neuro Virol 6(suppl 1): S8-S13.
37. Prendergast MA, Rogers DT, Mulholland PJ, Littleton JM, Wilkins LJ Jr, Self RL, Nath A (2002). Neurotoxic effects of the human immunodeficiency virust type-1 transcription factor Tat require function of a polyamine sensitive-site on the N-methyl-D-aspartate receptor. Brain Res 954: 300-307.
38. Puffer BA, Pohlmann S, Edinger AL, Carlin D, Sanchez MD, Reitter J, Watry DD, Fox HS, Desrosiers RC, Doms RW (2002). CD4 independence of simian immunodeficiency virus Envs is associated with macrophage tropism, neutralization sensitivity, and attenuated pathogenicity. J Virol 76: 2595-2605.
39. Romero IAM, Prevost MC, Perret E, Adamson P, Greenwood J, Couraud PO, Ozden S (2000). Interactions between brain endothelial cells and human T-cell leukemia virus type 1-infected lymphocytes: mechanisms of viral entry into the central nervous system. J Virol 74: 6021-6030.
40. Ryzhova EV, Crino P, Shawver L, Westmoreland SV, Lackner AA, González-Scarano F (2002). Simian immunodeficiency virus encephalitis: analysis of envelope sequences from individual brain multinucleated giant cells and tissue samples. Virology 297: 57-67.
41. Sacktor N, McDermott MP, Marder K, Schifitto G, Selnes OA, McArthur JC, Stern Y, Albert S, Palumbo D, Kieburtz K, De Marcaida JA, Cohen B, Epstein L (2002). HIV-associated cognitive impairment before and after the advent of combination therapy. J Neuro Virol 8: 136-142.
42. Sinclair E, Gray F, Ciardi A, Scaravilli F (1994). Immunohistochemical changes and PCR detection of HIV provirus DNA in brains of asymptomatic HIV positive patients. J Neuropath Exp Neurol 53: 43-50.
43. Smith DG, Guillemin GJ, Pemberton L, Kerr S, Nath A, Smythe GA, Brew BJ (2001). Quinolinic acid is produced by macrophages stimulated by platelet activating factor, Nef, and Tat. J Neuro Virol 7: 56-60.
44. Strizki JM, Albright AV, Sheng H, O'Connor M, Perrin L, González-Scarano F (1996). Infection of primary human microglia and monocyte-derived macrophages with human immunodeficiency virus type 1 isolates: evidence of differential tropism. J Virol 70: 7654-7662.
45. Thomas SA, Bye A, Segal MB (2001). Transport characteristics of the anti-human immunodeficiency virus nucleoside analog, abacavir, into brain and cerebrospinal fluid. J Pharm Exp Therapeu 298: 947-953.
46. Wiley CA, Schrier RD, Nelson JA, Lamper PW, Oldstone MBA (1986). Cellular localization of human immunodeficiency virus infection within the brains of acquired immune deficiency syndrome patients. Proc Natl Acad Sci U S A 83: 7089-7093.
47. Williams KC, Corey S, Westmoreland SV, Pauley D, Knight H, deBakker C, Alvarez X, Lackner AA (2001). Perivascular macrophages are the primary cell type productively infected by simian immunodeficiency virus in the brains of macaques: implications for the neuropathogenesis of AIDS. J Exp Med 193: 905-915.
48. Williams KC, Hickey WF (2002). Central nervous system damage, monocytes and macrophages, and neurological disorders in AIDS. Annu Rev Neurosci 25: 537-562.
49. Wong JK, Ignacio CC, Torriani F, Havlir D, Fitch NJ, Richman DD (1997). In vivo compartmentalization of human immunodeficiency virus: evidence from the examination of pol sequences from autopsy tissues. J Virol 71: 2059-2071.
50. Zhang PF, Bouma P, Park EJ, Margolick JB, Robinson JE, Zolla-Pazner S, Flora MN, Quinnan GV Jr (2002). A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. Virol 76: 644-655.